weight gain after glp 1 New study finds rapid gains are possible stopping GLP-1 drugs So what does this study

These medications do more than help people lose weight

For obesity management, NICE technology appraisals recommend liraglutide 3.0 mg or semaglutide 2.4 mg only as part of a specialist weight management service for adults with a BMI of 35 kg/m (or 32.5 kg/m for people from certain ethnic backgrounds) and at least one weight-related comorbidity

Low blood pressure, or hypotension, is generally defined as a systolic blood pressure below 90 mmHg or diastolic pressure below 60 mmHg, though symptoms matter more than absolute numbers

The widespread application of GLP-1 receptor agonists at the population level may impose significant financial pressure on pharmaceutical budgets, with modeling studies indicating that treating all eligible individuals with diabetes and obesity might need a 1020% rise in drug expenditures in several nations

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach

As mentioned above, GLP-1 drugs also act on the brain, mainly the hypothalamus